How do you decide if a full-time CRO is right for a PE-backed company when RevOps exists but no revenue leader in 2027?

The outcome you should expect

When a PE-backed company hires the right full-time CRO at the right moment, the visible outcome is a revenue engine that stops leaking value at the commercial edges — stalled contracts, underpriced renewals, forecasts nobody trusts — and starts converting RevOps' operational discipline into predictable, board-defensible growth. RevOps was already producing clean pipeline data, accurate stage definitions, and a functioning CRM; what it could not do is decide how to price a multi-year deal against a debt covenant, negotiate a channel partnership, or stand in front of the board and defend a forecast number under direct questioning from an operating partner. The CRO closes that gap. Within two to three quarters, a company that made the right call typically sees three concrete shifts: forecast accuracy tightens (the gap between "committed" and actual closed-won narrows because the CRO owns deal qualification standards rather than merely reporting them), average deal size and win rate on the largest 10–20% of the pipeline improve because someone with authority is negotiating those deals personally, and the board stops treating revenue reviews as an interrogation and starts treating them as a governance checkpoint. The outcome you should NOT expect is an instant reversal of a stalled growth curve — a new CRO, even a strong one, needs real ramp time to learn the fund's specific reporting cadence, exit thesis, and portfolio-level constraints before their judgment calls are reliable. If leadership or the board expects a turnaround within the first 60 days, that expectation itself is a signal the decision was made under panic rather than analysis, and it usually produces a rushed hire who is asked to fix a broken product or an unproven go-to-market motion — problems no revenue executive, fractional or full-time, can solve alone. The correct outcome is a company where RevOps and the CRO divide labor cleanly: RevOps owns the machinery (CRM hygiene, reporting infrastructure, process enforcement), and the CRO owns the judgment calls the machinery cannot make on its own — pricing, negotiation, headcount timing, and the narrative the fund hears every month.

What drives that outcome

Three forces interact to determine whether a full-time hire is the right call, and getting the sequencing wrong is the single most common reason PE-backed companies either overpay for a CRO too early or wait too long and lose deals in the meantime. The first force is scale: revenue and deal complexity have to be large enough that a part-time executive's bandwidth becomes the binding constraint, not the company's process maturity. The second is governance: the fund's board cadence, reporting standards, and exit timeline create a fixed set of obligations — weekly pipeline reviews, monthly KPI dashboards, quarterly strategic resets — that someone has to own continuously, not episodically. The third is trust: whether the existing RevOps leadership has the strategic range to be promoted, or whether an external hire is the only path to credibility with the fund's operating partners. These three forces don't move independently — a company can have plenty of scale but weak governance discipline, or strong RevOps trust but insufficient deal volume to justify the cost, and in either case, waiting is often the more capital-efficient move.

The interaction matters because a fund evaluating this decision is not asking "does the company need help" — RevOps existing at all proves someone already recognized that need. The fund is asking whether the help required has crossed from tactical (can be delivered part-time, on a defined mandate) to strategic (requires someone embedded full-time, accountable every week, empowered to negotiate on the company's behalf). A useful diagnostic: if the unresolved revenue problems are things RevOps can name precisely but cannot act on — "the sales team isn't following our process but we can't performance-manage them," or "we know this contract needs custom pricing but no one here can approve it" — that is a strategic gap, and it points toward a full-time hire. If the unresolved problems are things RevOps hasn't yet built — clean lead scoring, a working forecast model, defined sales stages — that is an infrastructure gap, and a CRO added on top of unfinished infrastructure will spend their first six months doing RevOps' job instead of their own.

Benchmarks and realistic ranges

Concrete thresholds help make this decision less subjective, even though every fund's thesis shifts the exact numbers. On revenue scale, companies below roughly $5–8M in ARR rarely justify a full-time CRO — the fixed cost of a senior executive salary, often falling in a $200,000–$400,000+ base range before equity or carry, outweighs what a founder-led or fractional structure can deliver at that size. Between roughly $8M and $15M ARR, most PE-backed companies sit in a genuine gray zone where a fractional or interim leader working meaningfully more than the typical 10–20 hours a week is the better fit — enough authority to unblock stalled deals without the fixed cost of a full-time seat. Above roughly $15–30M ARR, or once the sales organization exceeds about 10–15 quota-carrying reps, most funds shift toward full-time, because deal volume and board obligations exceed what any part-time arrangement can sustain. On hold period, funds running shorter three-to-five-year holds tend to push for a full-time hire earlier because they need visible revenue acceleration well before the exit process starts; funds with longer seven-plus-year holds can tolerate a fractional or interim structure longer because they have more runway to build organically. On engagement structure, a common PE pattern is a defined three-month fractional mandate tied to a specific, measurable outcome — closing a named list of stalled deals, rebuilding the compensation plan, fixing forecast accuracy — with conversion to full-time contingent on hitting that mandate rather than on tenure or relationship. A rough rule some operating partners apply: if a fractional leader closes or unblocks a meaningful multiple of their engagement cost in pipeline within the first 90 days, that is treated as evidence the role should become full-time; if their contribution stayed advisory, the fund typically re-evaluates at the six-month mark instead of converting immediately. On promotion versus external hire, promoting an existing RevOps leader into the CRO seat works often enough to be a real option, but only when that leader has already shown strategic range beyond operations — has personally renegotiated a contract, redesigned a pricing structure, or made a judgment call that changed a deal outcome — and even then, funds commonly pair the promotion with several months of external fractional mentorship to close the gap in board-level communication and commercial negotiation experience that most RevOps backgrounds don't build.

Risks, edge cases, and failure modes

The most common and costly mistake is hiring a full-time CRO to fix a problem that isn't a revenue-leadership problem at all. If product-market fit is unproven, or the core product doesn't yet solve the customer's problem reliably, no CRO — fractional or full-time — can manufacture durable revenue growth on top of it; the money is better spent validating the offer than staffing a leadership seat to sell it harder. A related failure mode is hiring too early relative to RevOps' own maturity: if the CRM is unreliable, if there's no consistent lead-scoring or stage definition, or if forecast numbers are essentially guesses, a new CRO's first two quarters get consumed rebuilding infrastructure RevOps should have owned, and the fund sees an expensive executive doing a manager's job. The inverse failure — waiting too long — shows up as a growing "bow wave" of stalled late-stage deals that sit unclosed because no one has the authority to offer the pricing flexibility, indemnification terms, or multi-year structure a sophisticated buyer's procurement team demands; every quarter that bow wave grows, the fund is realizing less of the value RevOps' pipeline already represents. A subtler risk is choosing the wrong candidate profile for the fund's actual timeline: hiring a long-term culture-building CRO when the fund is eighteen months from an exit and actually needs an interim operator focused on due-diligence readiness, or the reverse — installing an interim "fix it and leave" leader when the company needs someone to build a durable team and process for a longer hold. Compensation misalignment is another common failure: a base-heavy package on a short hold period can leave the executive under-incentivized to push hard toward an exit event, while a carry-heavy package on a long hold with high near-term cash needs can make the role unattractive to strong external candidates. Finally, promoting an internal RevOps leader without adequate support is a recognized failure pattern — if that leader cannot develop board-level communication and commercial negotiation ability fast enough, the fund can lose two quarters or more of revenue momentum discovering the promotion didn't work, which is often worse than making the harder decision to hire externally from the start.

A practical rollout plan

Whichever direction the decision goes, the rollout should be sequenced, not announced all at once, because the fund, the board, RevOps, and the sales team all need different signals at different times. Start by having RevOps produce an honest capability audit — not a defense of their work, but a clear-eyed list of which revenue problems are infrastructure gaps (fixable within the team) versus strategic gaps (requiring executive authority RevOps doesn't have). Bring that audit to the fund's operating partner alongside the specific board and reporting obligations tied to the current hold-period timeline, because the governance requirement is often the deciding factor even when the revenue-scale numbers are ambiguous. If the decision leans toward hiring, structure it as a defined-mandate engagement first wherever possible — a fractional or interim leader given one measurable, time-boxed objective — rather than committing to a full-time seat on the first attempt; this de-risks the decision for both the company and the candidate. Only after that mandate is met, and only after RevOps' foundational infrastructure is confirmed solid, should the company convert to a full-time search, with the search criteria explicitly built around the fund's actual hold-period and exit thesis rather than a generic "senior revenue leader" job description.

Once a full-time CRO is in seat, the first quarter should follow a strict cadence rather than an open-ended "listening tour": an early audit period focused on finding revenue leaks in the existing pipeline and compensation structure, a middle period focused on producing at least one visible, board-recognizable win — closing a previously stalled deal, correcting an underpriced renewal, tightening the forecast methodology — and a final period focused on publishing a forward-looking revenue plan explicitly tied to the fund's hold-period math. Throughout, RevOps should be repositioned as the CRO's operating layer, not a parallel reporting line, so the company doesn't end up with two competing narratives about what the pipeline actually shows.

Related questions

What ARR threshold typically triggers a full-time CRO hire at a PE-backed company?

Most funds see the case strengthen between roughly $15–30M ARR, once deal volume, sales headcount, and board reporting obligations exceed what a part-time or fractional leader can realistically carry alongside other clients.

Can a RevOps leader be promoted into the CRO role instead of hiring externally?

Yes, but only when they've shown strategic range beyond operations — contract negotiation, pricing decisions — and even then funds usually pair the promotion with several months of external mentorship to close board-communication gaps.

How does a PE fund's hold period change the urgency of the CRO decision?

Shorter three-to-five-year holds push funds toward hiring full-time sooner to show revenue acceleration before an exit process; longer seven-plus-year holds tolerate fractional leadership longer since there's more time to build organically.

What's the difference between an interim and a full-time CRO in a PE-backed company?

An interim CRO is full-time but temporary, usually brought in to prepare the revenue function for due diligence ahead of a sale; a full-time CRO is a permanent hire expected to build lasting team, process, and culture.

What signals suggest a company should stay with a fractional leader instead of hiring full-time?

If RevOps is still building basic infrastructure — CRM hygiene, lead scoring, a reliable forecast model — a full-time CRO will be underutilized; a fractional leader mentoring that build-out is more capital-efficient at that stage.

FAQ

Does having RevOps already in place mean the company isn't ready for a CRO? No — RevOps existing is usually a prerequisite, not a substitute. RevOps builds and maintains the operational machinery (data, process, reporting), while a CRO makes the strategic and commercial calls that machinery surfaces but can't resolve on its own, like pricing, negotiation authority, and board narrative.

How much does a full-time CRO typically cost a PE-backed company? Base compensation commonly falls in a wide range depending on company size and fund thesis, often landing somewhere in the low-to-high hundreds of thousands annually before equity or carry is added. The exact structure — more base versus more equity — usually tracks the fund's hold-period length.

Should the CRO decision be made by the founder, the board, or the fund? In a PE-backed structure, the fund's operating partners and the PE-appointed board are typically the real decision-makers, since they control budget approval and are accountable for the company's performance against the fund's own return targets — not just the founder's preference.

What happens if a company hires a full-time CRO too early? The CRO ends up spending their first two quarters rebuilding basic RevOps infrastructure — CRM hygiene, lead scoring, forecast discipline — instead of doing strategic, revenue-leadership work, which makes an expensive hire look like an expensive manager.

Is a three-month fractional trial period a normal part of this decision? Yes — it's a common PE pattern. A fractional or interim leader is given a specific, measurable mandate (e.g., closing a defined set of stalled deals or rebuilding the compensation plan), and hitting that mandate is often the trigger for converting the role to full-time.

Can the RevOps team run the revenue forecast without a CRO at all? RevOps can build and maintain the forecast model, but in a PE-backed context the board typically expects someone to personally defend and own the accuracy of that forecast under direct questioning — a role RevOps usually isn't positioned or empowered to fill on its own.

Sources

• https://www.investopedia.com/terms/p/privateequity.asp
• https://hbr.org/topic/subject/private-equity
• https://www.mckinsey.com/industries/private-equity-and-principal-investors/our-insights
• https://www.bain.com/insights/topics/private-equity/
• https://www.gartner.com/en/sales
• https://www.forbes.com/sites/forbesbusinesscouncil/
• https://sloanreview.mit.edu/
• https://www.sec.gov/

Related on PULSE

• Fractional vs. full-time CRO: how to structure the engagement
• Building a RevOps function that a future CRO can actually use
• How PE operating partners evaluate portfolio company revenue leaders
• Setting a 90-day plan for an incoming revenue executive
• When to promote from within vs. hire a revenue leader externally